1L CT (HR+HER2-): Active treatments
Capecitabine
O’Shaughnessy et al The Oncologist 2012; Fumoleau et al EJC 2004
•
Capecitabine has substantial antitumor activity in 1L MBC (prospective, randomized, phase II/III
CTs) as monotherapy and in combination with biologic and novel agents
•
CAPE monotherapy has favorable safety profile, lacking myelosuppression and alopecia, and does
not compromise the administration of further lines of CT, is suitable for long-term administration
without the cumulative toxicity that can limit the prolonged use of other CTs
